###begin article-title 0
###xml 62 67 <span type="species:ncbi:9606">human</span>
Evidence for a wide extra-astrocytic distribution of S100B in human brain
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 205 210 <span type="species:ncbi:9606">human</span>
###xml 304 309 <span type="species:ncbi:9606">human</span>
S100B is considered an astrocytic in-situ marker and protein levels in cerebrospinal fluid (CSF) or serum are often used as biomarker for astrocytic damage or dysfunction. However, studies on S100B in the human brain are rare. Thus, the distribution of S100B was studied by immunohistochemistry in adult human brains to evaluate its cell-type specificity.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 272 277 <span type="species:ncbi:9606">human</span>
Contrary to glial fibrillary acidic protein (GFAP), which selectively labels astrocytes and shows only faint ependymal immunopositivity, a less uniform staining pattern was seen in the case of S100B. Cells with astrocytic morphology were primarily stained by S100B in the human cortex, while only 20% (14-30%) or 14% (7-35%) of all immunopositive cells showed oligodendrocytic morphology in the dorsolateral prefrontal and temporal cortices, respectively. In the white matter, however, most immunostained cells resembled oligodendrocytes [frontal: 75% (57-85%); temporal: 73% (59-87%); parietal: 79% (62-89%); corpus callosum: 93% (86-97%)]. S100B was also found in ependymal cells, the choroid plexus epithelium, vascular endothelial cells, lymphocytes, and several neurones. Anti-myelin basic protein (MBP) immunolabelling showed an association of S100B with myelinated fibres, whereas GFAP double staining revealed a distinct subpopulation of cells with astrocytic morphology, which solely expressed S100B but not GFAP. Some of these cells showed co-localization of S100B and A2B5 and may be characterized as O2A glial progenitor cells. However, S100B was not detected in microglial cells, as revealed by double-immunolabelling with HLA-DR.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 329 334 <span type="species:ncbi:9606">human</span>
S100B is localized in many neural cell-types and is less astrocyte-specific than GFAP. These are important results in order to avoid misinterpretation in the identification of normal and pathological cell types in situ and in clinical studies since S100B is continuously used as an astrocytic marker in animal models and various human diseases.
###end p 7
###begin title 8
1. Background
###end title 8
###begin p 9
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
S100B protein is a Ca2+, Cu2+ and Zn2+ binding member of the S100-calmodulin-troponin superfamily and is primarily found in high abundance within the nervous system [1].
###end p 9
###begin p 10
###xml 331 332 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 423 424 423 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 553 554 553 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
21 kDa homodimers are the predominant form in which the protein exists within cells. A number of intracellular growth-associated target proteins have been revealed, such as growth-associated protein 43 (GAP-43), the regulatory domain of protein kinase C (PKC), the anti-apoptotic factor Bcl-2 or the tumour suppressor protein P53 [2]. S100B has also been found to regulate protein ubiquitination via interaction with Sgt1 [3] and regulate the assembly of cytoskeleton components such as microtubules, glial fibrillary acidic protein (GFAP) or vimentin [4].
###end p 10
###begin p 11
###xml 505 506 505 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 653 654 653 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 655 656 655 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1088 1089 1074 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1090 1091 1076 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
However, S100B is not only implicated in the regulation of intracellular processes, but, it is also a secretory protein and exhibits cytokine-like activities, which mediate the interactions among glial cells and between glial cells and neurones. These effects are induced, in part, by interaction of S100B with the receptor for advanced glycation end products (RAGE), a multiligand receptor that has been shown to transduce inflammatory stimuli and effects of several neurotrophic and neurotoxic factors [2]. Secretion of S100B from astrocytes is stimulated under metabolic stress (oxygen, serum and glucose deprivation) and is suppressed by glutamate [5,6]. S100B acts in a dose-dependent manner: Nanomolar levels stimulate neurite growth and promote neurone survival. However, micromolar levels result in opposite effects and can even induce neuronal apoptosis, leading to the induction of pro-inflammatory cytokines such as interleukin1beta (IL-1beta) or tumour necrosis factor alpha (TNF-alpha), and inflammatory stress-related enzymes such as inducible nitric oxide synthase (iNOS) [7,8].
###end p 11
###begin p 12
###xml 222 223 222 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 635 637 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 893 895 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 610 615 <span type="species:ncbi:9606">human</span>
###xml 731 736 <span type="species:ncbi:9606">human</span>
High levels of S100B in cerebrospinal fluid (CSF) and peripheral blood have been observed in clinical research on Alzheimer's disease, stroke, traumatic brain injury, meningoencephalitis, mood disorders and schizophrenia [9-13]. Elevated levels of S100B have been increasingly considered a biomarker for astrocytic damage or dysfunction in this context. This may have arisen from several postmortem studies on Alzheimer's disease and Down's syndrome describing predominant S100B immunostaining in reactive astrocytes surrounding neuritic plaques [14-16]. Other studies on the cell-type specificity of S100B in human brain are rare [17,18]. The cell-type specific localization of S100B in white matter has been minimally studied in human brain. However, higher contents of S100 have been found in white matter homogenates relative to cortex homogenates by the discoverer of the protein family [19].
###end p 12
###begin p 13
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 421 423 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
In addition, it is sometimes overlooked that S100B containing cell types have also been identified outside the central nervous system and there are physiological stimuli for a release of S100B into the serum or CSF, which are not related to central nervous system diseases. Examples are physical exercise [20], stress [21,22], fasting [23], critically ill patients [24], cardiac arrest [25] and extracranial injuries [26,27] without brain injury.
###end p 13
###begin p 14
###xml 98 103 <span type="species:ncbi:9606">human</span>
The aim of the present work was to analyze the immunohistochemical distribution of S100B in adult human brain. We investigated telencephalic and diencephalic regions, including white matter of 14 healthy adults, to evaluate the cell-type specificity of S100B.
###end p 14
###begin title 15
2. Results
###end title 15
###begin title 16
Western blot analysis
###end title 16
###begin p 17
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 157 162 <span type="species:ncbi:9606">human</span>
Using the S100B antibody obtained from DAKO, we observed a single strong band with a molecular mass of about 10 kDa, representing the authentic molecule, in human adult brain (Figure 1). This is in accordance with the immunoblotting analysis performed by the manufacturer of the antibody (DAKO, Glostrup, Denmark, see data sheet) using recombinant S100A1, S100A2, S100A4 and S100A6, where no cross-reaction with other S100 proteins was observed.
###end p 17
###begin title 18
Preabsorption
###end title 18
###begin p 19
###xml 103 108 <span type="species:ncbi:9606">human</span>
No specific immunostaining was observed after preabsorption of the S100B antibody with the recombinant human-S100B protein.
###end p 19
###begin title 20
Immunohistochemistry
###end title 20
###begin p 21
###xml 79 80 79 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 85 86 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 282 287 282 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2e, g</xref>
###xml 817 822 817 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b, d</xref>
###xml 1013 1021 1013 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2c, e, f</xref>
###xml 1130 1135 1130 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2f, h</xref>
###xml 1233 1238 1233 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2i, k</xref>
###xml 406 411 <span type="species:ncbi:9606">human</span>
The differential S100B- and GFAP-immunostaining pattern is summarized in Table 1 and 2. GFAP immunohistochemistry selectively labelled astrocytes and their processes (Figure 2a), showed only faint ependymal immunopositivity and was negative in the choroid plexus epithelium (Figure 2e, g). In contrary, a less uniform staining pattern was seen in the case of S100B. Cells with astrocytic morphology in the human cortex primarily stained positive for S100B, while only 20% (14-30%) or 14% (7-35%) of all immunopositive cells showed oligodendrocytic morphology in the dorsolateral prefrontal and temporal cortex, respectively. In the white matter, however, most immunostained cells resembled oligodendrocytes [frontal: 75% (57-85%); temporal: 73% (59-87%); parietal: 79% (62-89%); corpus callosum: 93% (86-97%); Figure 2b, d]. Both GFAP- and S100B-immunostaining were seen in the subependymal layer and the perivascular (glia limitans) compartment and the perivascular membrane formed by astrocytic endfeet (Figure 2c, e, f). Of note, we observed strong S100B immunopositivity of the ependymal and choroids plexus epithelia (Figure 2f, h). In addition, S100B was also found in a few neurones and a subpopulation of lymphocytes (Figure 2i, k). By contrast, GFAP expression was detected neither in neurones nor in lymphocytes by the monoclonal antibody. The intracellular localization also varied: S100B was found in the nucleus and cytoplasm whereas GFAP was confined to the cytoplasm.
###end p 21
###begin title 22
Double immunolabelling and immunofluorescence staining
###end title 22
###begin p 23
###xml 175 180 175 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a, b</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3f</xref>
###xml 403 408 403 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3c, d</xref>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3e</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3g</xref>
Double immunolabelling revealed a distinct subpopulation of cells with astrocytic morphology, which were either positive for S100B or GFAP, or expressed both antigens (Figure 3a, b). Some of these were A2B5-immunopositive O2A glial progenitor cells (Figure 3f). S100B-positive fibres were also observed, which correspond to myelinated fibers as shown by double immunolabelling for S100B and MBP (Figure 3c, d). Oligodendrocytic S100B expression was confirmed by co-localization with MOG (Figure 3e). However, no microglial S100B immunolabelling was observed by HLA-DR double immunostaining (Figure 3g).
###end p 23
###begin title 24
3. Discussion and Conclusion
###end title 24
###begin p 25
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 1184 1186 1184 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1367 1369 1367 1369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1370 1372 1370 1372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1373 1375 1373 1375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1376 1378 1376 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1398 1400 1398 1400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1523 1525 1523 1525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 118 123 <span type="species:ncbi:10090">mouse</span>
###xml 125 128 <span type="species:ncbi:10116">rat</span>
###xml 130 133 <span type="species:ncbi:9685">cat</span>
###xml 345 350 <span type="species:ncbi:9606">human</span>
###xml 493 498 <span type="species:ncbi:9606">human</span>
###xml 1497 1501 <span type="species:ncbi:10090">mice</span>
###xml 1618 1622 <span type="species:ncbi:10116">rats</span>
The cell-type specific localization of S100B in the brain has already been investigated in various species, including mouse, rat, cat, and lizard [28-33]. These studies found S100B in all glial cells, including astrocytes, ependymal cells, oligodendrocytes, microglial and Schwann cells. Studies on the cell-type specific expression of S100B in human brain are rare, but astrocytic and oligodendrocytic expression have been observed [23,47]. Immunohistochemical postmortem studies on S100B in human temporal cortex in Alzheimer's disease and Down's syndrome may have led to the assumption that S100B is an astrocyte-specific marker (see introduction) [13,28,44]. This is in accordance with our findings on grey matter, indicating a predominantly astrocytic S100B expression pattern in the dorsolateral prefrontal and temporal cortex of individuals without neurological or psychiatric disorders. However the majority of S100B immunopositive cells in the white matter resembled oligodendrocytes, which is in accordance with an early publication by Moore et al. (the discoverer of S100) who observed a higher content of S100 in white matter homogenates relative to cortical homogenates [19]. It has been demonstrated in rodents that S100B is primarily confined to immature oligodendrocytes, which may be activated in the context of a regenerative myelination processes [28,31,34,35]. Deloulme et al. [28] detected S100B protein in up to 40% of MBP-positive oligodendrocytes in the corpus callosum of mice and Rickmann et al. [34] found an association of S100B with paranodal loops and outer mesaxons of myelin sheaths in rats by electron microscopic immunohistochemistry.
###end p 25
###begin p 26
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 778 780 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 50 53 <span type="species:ncbi:10116">rat</span>
###xml 128 133 <span type="species:ncbi:9606">human</span>
###xml 236 241 <span type="species:ncbi:9606">human</span>
###xml 299 304 <span type="species:ncbi:10090">mouse</span>
###xml 317 320 <span type="species:ncbi:10116">rat</span>
###xml 427 432 <span type="species:ncbi:9606">human</span>
###xml 473 478 <span type="species:ncbi:10090">mouse</span>
###xml 772 776 <span type="species:ncbi:10090">mice</span>
Microglial staining has only been detected in the rat by Adami et al. so far, but has not been observed in our present study on human brain [30]. Our study is the first reporting of a small subpopulation of S100B containing neurones in human brain tissue. This is in accordance with findings in the mouse [29,36] and rat [33,37], but is in contrary to Li et al., who was unable to detect S100B immunopositive neurones in adult human brain [18]. Using a different antibody (mouse monoclonal anti-S100B from IBL, Minnesota) and the absence of antigen demasking techniques in the study by Li et al. might explain these different observations, as the importance of antigen retrieval methods to detect S100B immunopositive neurones has already been addressed by Yang et al. in mice [37].
###end p 26
###begin p 27
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 136 139 <span type="species:ncbi:10116">rat</span>
###xml 560 565 <span type="species:ncbi:9606">human</span>
###xml 608 613 <span type="species:ncbi:10090">mouse</span>
###xml 618 621 <span type="species:ncbi:10116">rat</span>
Interestingly, the ependyma and the choroid plexus epithelia were strongly S100B immunopositive in our study as previously noted in the rat [38]. The surface ependyma is known to express epithelial markers and faint GFAP-staining. It is considered to be developmentally related to astrocytes, while the choroid plexus epithelium is a specialized ependyma, which differs from the surface ependyma: vimentin, cytokeratin and S100B continue to be expressed, but GFAP is not expressed [39]. Thus, the observed distribution pattern of S100B in the present study on human brain completely matches that reported in mouse and rat, indicating that cellular function might be very similar among mammalians.
###end p 27
###begin p 28
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
Our study reveals a subpopulation of cells with astrocytic morphology, which were only immunopositive for S100B but not for GFAP. One explanation might be that some cells with astrocytic morphology were S100B- and A2B5-immunopositive O2A glial progenitor cells, which do not express GFAP [40].
###end p 28
###begin p 29
###xml 624 626 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 772 773 772 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
In conclusion, S100B is a less astrocyte-specific marker than GFAP. Therefore, it should not be generally assumed that astrocytic damage or dysfunction is the main source for increased S100B concentrations in the case of studies with plasma, serum or cerebrospinal fluid. S100B may also be released during non-astrocyte cell death as it is also localized in O2A glial progenitor cells, oligodendrocytes, ependymal and plexus epithelial cells and neurones. In addition, S100B protein has also been noted outside the central nervous system. Immunocytochemical studies detected S100B in 5-25% of CD8+ peripheral blood T cells [41], in adipose tissue, melanocytes, injured myocardium, satellite cells of dorsal root ganglia and Schwann-cells of the peripheral nervous system [2]. There is little information about the functional implications, but all these cell types are potential sources for S100B in serum.
###end p 29
###begin p 30
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 374 396 374 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">monoclonal anti-brain </italic>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 217 222 <span type="species:ncbi:9606">human</span>
In contrast, only minor sources of GFAP have been detected outside the central nervous system. Traces of GFAP have been found in the peripheral nervous system, macrophages, lymphocytes, lens epithelial cells, and few human breast myoepithelial cells [42-45]. Moreover, the peripheral GFAP is a shorter protein version and may be antigenically and structurally different, as monoclonal anti-brain GFAP antibodies have failed to recognize peripheral GFAP [46,47].
###end p 30
###begin p 31
###xml 306 311 <span type="species:ncbi:9606">human</span>
In summary, serum and CSF S100B, different from GFAP, has many putative cellular sources. This is important to avoid misinterpretation of normal and pathological cell type identifications in situ and in clinical studies since S100B is continuously used as an astrocytic marker in animal models and various human diseases.
###end p 31
###begin title 32
4. Methods
###end title 32
###begin title 33
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human brain tissue for Western blot analysis and immunofluorescence staining
###end title 33
###begin p 34
###xml 27 32 <span type="species:ncbi:9606">woman</span>
The brain of a 32 year old woman (who died from acute myocarditis associated with lupus) was removed from the cranium within 20 hrs after death, dissected into small pieces, snap-frozen in liquid nitrogen and stored.
###end p 34
###begin title 35
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human brain tissue for immunohistochemistry
###end title 35
###begin p 36
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 248 253 <span type="species:ncbi:9606">human</span>
Postmortem brain tissue of 14 individuals without neurological or psychiatric disorders was used for the present study (mean age = 58.4 years; 7 males, 7 females). All brains were obtained from the Magdeburg Brain Collection. The collection of the human brain material was done in accordance with German laws and the rules outlined by the local ethics committee. Brains were removed within 48 hrs after death. The tissue preparation was performed as previously described [48]. Briefly, brains were fixed in toto in 8% phosphate-buffered formaldehyde (pH 7.0) for 3 months. After embedding the brains in paraplast, serial coronal 20 mum thick whole brain sections were cut on a microtome and mounted. For immunohistochemical staining, sections about 1 cm rostral to the genu of the corpus callosum and sections containing the hippocampus, as well as thalamus and lateral ventricles at the level of the mamillary bodies were selected.
###end p 36
###begin p 37
###xml 0 13 0 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Blood smears </italic>
Blood smears from two healthy subjects were stained for S100B for closer identification of S100B immunopositive white blood cells, which were found in the vessels of brain sections. The blood smears were fixed in methanol for 1 h.
###end p 37
###begin title 38
Western blot analysis
###end title 38
###begin p 39
###xml 1137 1148 <span type="species:ncbi:3704">horseradish</span>
###xml 1176 1182 <span type="species:ncbi:9986">rabbit</span>
###xml 1270 1281 <span type="species:ncbi:3704">horseradish</span>
Frozen tissue samples from the temporal cortex and cerebellum was homogenized in lysis buffer [10 mM Tris (pH 7.4), 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholat, 2.5 mM sodium pyrophosphate, 1 mM orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 1 mug/ml leupeptin, and 10 mug/ml aprotinin, 1 mM DTT], and incubated on ice for 30 minutes. After centrifugation at 13,000 rpm for 15 minutes, the supernatant was collected to measure the total protein content. Protein concentration was measured by Bradford assay, with BSA as standard. Twenty micrograms of protein were loaded on 10% SDS-polyacrylamide gels for electrophoresis. After separation, proteins were transferred to a nitrocellulose membrane (Hybond C, Amersham Pharmacia Biotech, Freiburg, Germany) at 150 mA for 2 hours. Western blot analysis was done after blocking the membrane with 5% skim milk in TBST buffer for 1 hour. The membrane was incubated with the specific S100B antibody at 4degreesC overnight (DAKO, Glostrup, Denmark, dilution 1:500). The membrane was washed four times in TBST buffer. Secondary detection was performed using horseradish peroxidase-conjugated anti-rabbit immunoglobulin G (1:2,000; Amersham Pharmacia Biotech). After four washings with TBST, horseradish peroxidase activity was visualized by applying enhanced chemiluminescent substrate (Amersham Pharmacia Biotech) followed by exposure of the membrane to X-ray film.
###end p 39
###begin title 40
Immunohistochemistry - Single staining
###end title 40
###begin p 41
###xml 247 248 247 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 249 251 249 251 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1122 1124 1116 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1127 1140 1121 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Preabsorption</italic>
###xml 1395 1410 1389 1404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Double staining</italic>
###xml 372 376 <span type="species:ncbi:9925">goat</span>
###xml 563 569 <span type="species:ncbi:9986">rabbit</span>
###xml 587 592 <span type="species:ncbi:9606">human</span>
###xml 716 721 <span type="species:ncbi:10090">mouse</span>
###xml 727 732 <span type="species:ncbi:9606">human</span>
###xml 1272 1277 <span type="species:ncbi:9606">human</span>
###xml 1578 1583 <span type="species:ncbi:10090">mouse</span>
###xml 1593 1599 <span type="species:ncbi:9986">rabbit</span>
Neighbouring sections were used for S100B or GFAP single-staining. Formalin-fixed tissue sections were deparaffinized and antigen demasking was performed by boiling the sections for 4 min in 10 mM citrate buffer (pH 6.0). Preincubation with 1.5% H2O2 for 10 min to block endogenous peroxidase activity was followed by blocking of nonspecific binding sites with 10% normal goat serum for 60 min and repeated washings with PBS. The primary antibody was diluted in PBS and applied for 48 h at 4degreesC (both antibodies were from DAKO, Glostrup, Denmark: polyclonal rabbit anti-recombinant human S100B, according to the manufacturer non cross-reactive with S100A1, S100A2, S100A4, and S100A6, dilution 1:50; monoclonal mouse anti-human brain glial fibrillary acidic protein (GFAP), dilution 1:100). Thereafter, sections were processed with the LSAB (labelled streptavidin biotin) method (DAKO, Glostrup, Denmark) and the reaction product was visualized with 3,3-diaminobenzidine. The colour reaction of the S100B staining was enhanced by adding 2 ml of a 0.5% (v/v) nickel ammonium sulphate solution to the diaminobenzidine [49]. Preabsorption: Specificity of the S100B immunoreaction was controlled by preabsorption of 2 ml antibody working dilution with 0.8 mg recombinant human-S100B (Biotrend, Cologne, Germany) for 24 h. No specific staining was observed after preabsorption with the protein. Double staining: Anti S100B primary antibody was applied for 48 h at 4degreesC. Thereafter, sections were incubated with EnVision Labelled Polymer (alkaline phosphatase-labelled anti-mouse and anti-rabbit antibodies, DAKO, Glostrup, Denmark) and the reaction product was visualized with Liquid permanent red (DAKO, Glostrup, Denmark). Subsequent GFAP immunostaining was performed according to the single-staining protocol after antibody elution with 0.1 M glycine-HCl for 10 min (pH 2.0). Counterstaining was performed with 50% (v/v) Harris Haematoxylin Solution (Sigma, St. Louis, USA) for 30 s.
###end p 41
###begin title 42
Immunofluorescence staining
###end title 42
###begin p 43
A tissue sample from the temporal cortex and adjacent white matter was fixed in 4% buffered paraformaldehyde (pH 7.4) at 4degreesC overnight, cryoprotected in a solution of 30% sucrose (Merck, Darmstadt, Germany) in 0.4% buffered paraformaldehyde (pH 7.4) for 2 days, and rapidly frozen at -20degreesC using 2-methylbutane (Roth, Karlsruhe, Germany). Serial sagittal 20 mum thick sections were cut on a cryostat (Jung Frigocut 2800 E, Leica, Bensheim, Germany).
###end p 43
###begin p 44
###xml 95 101 <span type="species:ncbi:9986">rabbit</span>
###xml 119 124 <span type="species:ncbi:9606">human</span>
###xml 184 189 <span type="species:ncbi:10090">mouse</span>
###xml 292 297 <span type="species:ncbi:10090">mouse</span>
###xml 415 420 <span type="species:ncbi:10090">mouse</span>
###xml 500 505 <span type="species:ncbi:10090">mouse</span>
###xml 511 516 <span type="species:ncbi:9606">human</span>
###xml 638 642 <span type="species:ncbi:9925">goat</span>
###xml 850 854 <span type="species:ncbi:9925">goat</span>
###xml 860 866 <span type="species:ncbi:9986">rabbit</span>
###xml 890 894 <span type="species:ncbi:9925">goat</span>
###xml 900 905 <span type="species:ncbi:10090">mouse</span>
Free-floating sections were washed and incubated with the corresponding antibodies: polyclonal rabbit anti-recombinant human S100B (DAKO, Glostrup, Denmark, dilution 1:50), monoclonal mouse anti-myelin basic protein (anti-MBP, Chemicon, Hampshire, United Kingdom, dilution 1:100), monoclonal mouse anti-myelin oligodendrocyte glycoprotein (anti-MOG, Chemicon, Hampshire, United Kingdom, dilution 1:500), monoclonal mouse anti-A2B5 (Chemicon, Hampshire, United Kingdom, dilution 1:100), or monoclonal mouse anti-human HLA-DR-alpha-chain (Clone TAL.1B5, DAKO, Glostrup, Denmark, dilution 1:1000) in PBS with 0.3% Triton X-100 and 1% normal goat serum overnight at 4degreesC. Following this, slices were washed in PBS (3 x 5 min) and incubated overnight with a combination of secondary antibodies (Molecular Probes, Gottingen, Germany, dilution 1:500): goat anti-rabbit-IgG Alexa Fluor 546 or goat anti-mouse-IgG Alexa Fluor 488. Sections were examined using a fluorescence microscope (Axiophot, Zeiss, Germany) equipped with fluorescein, rhodamine and DAPI optics. Control reactions (substitution of the primary antisera with PBS) yielded negative results, i.e. no specific immunostaining was seen in these sections.
###end p 44
###begin title 45
Cytological classification
###end title 45
###begin p 46
###xml 4 31 4 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cytological classification </italic>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
The cytological classification of immunopositive cells as neurones, astrocytes, oligodendrocytes or microglia was performed according to established cytomorphological criteria [50]: Neuronal nuclei are large, round with a single prominent nucleolus ("fried-egg" nuclei) and are surrounded by substantial cytoplasm. Astrocytes have less cytoplasm surrounding large, more or less rounded nuclei and exhibit many star-shaped processes. Fibrous astrocytes are found predominantly in the white matter; they possess numerous elongated processes. Protoplasmic astrocytes are present among collections of neuronal cell bodies (grey matter). Their processes are less numerous and considerably more swollen in appearance than those of fibrous astrocytes. Oligodendrocytes are associated with fibre tracts in typical "pearl necklet" alignment. They are small spheroid glial cells with round, lymphocyte-like nuclei, a small cytoplasmic rim and few processes (less than astrocytes).
###end p 46
###begin title 47
Abbreviations
###end title 47
###begin p 48
CSF: cerebrospinal fluid
###end p 48
###begin p 49
DLPF: dorsolateral prefrontal
###end p 49
###begin p 50
GAP-43: growth-associated protein 43
###end p 50
###begin p 51
GFAP: glial fibrillary acidic protein
###end p 51
###begin p 52
IL-1beta: interleukin1beta
###end p 52
###begin p 53
iNOS: inducible nitric oxide synthase
###end p 53
###begin p 54
MBP: myelin basic protein
###end p 54
###begin p 55
MOG: myelin oligodendrocyte glycoprotein
###end p 55
###begin p 56
PKC: protein kinase C
###end p 56
###begin p 57
RAGE: receptor for advanced glycation end products
###end p 57
###begin p 58
S.D.: standard deviation
###end p 58
###begin p 59
TNF-alpha: tumour necrosis factor alpha
###end p 59
###begin title 60
Authors' contributions
###end title 60
###begin p 61
JS, HGB and BB conceived and designed the study. JS interpreted the results, performed the statistical analysis, created the figures and drafted the manuscript. AB and RB evaluated the slides. HB documented the results and contributed to the interpretation of results. CM performed the neuropathological examination and Western blot analysis. GK was responsible for the immunofluorescence staining. All authors read and approved the final manuscript.
###end p 61
###begin title 62
Acknowledgements
###end title 62
###begin p 63
The Saxony-Anhalt Ministry of Research (XN3594O/0405M, N2-OGU), German Ministry of Research (BrainNet) and Stanley Foundation supported the present study. We thank Dr. Alan Richardson-Klavehn for revising the English language of the manuscript. Henrik Dobrowolny, Sieglinde Funke, Bianca Ketzler, Kathrin Paelchen and Renate Stauch provided excellent technical assistance.
###end p 63
###begin article-title 64
A soluble protein characteristic of the nervous system
###end article-title 64
###begin article-title 65
S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles
###end article-title 65
###begin article-title 66
Calcium-regulated interaction of Sgt1 with S100A6 (calcyclin) and other S100 proteins
###end article-title 66
###begin article-title 67
S-100 protein, but not calmodulin, binds to the glial fibrillary acidic protein and inhibits its polymerization in a Ca(2+)-dependent manner
###end article-title 67
###begin article-title 68
Active secretion of S100B from astrocytes during metabolic stress
###end article-title 68
###begin article-title 69
High glutamate decreases S100B secretion by a mechanism dependent on the glutamate transporter
###end article-title 69
###begin article-title 70
S100beta induces neuronal cell death through nitric oxide release from astrocytes
###end article-title 70
###begin article-title 71
S100B proteins that lack one or both cysteine residues can induce inflammatory responses in astrocytes and microglia
###end article-title 71
###begin article-title 72
Sequential analyses of neurobiochemical markers of cerebral damage in cerebrospinal fluid and serum in CNS infections
###end article-title 72
###begin article-title 73
Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease
###end article-title 73
###begin article-title 74
S100B is increased in mood disorders and may be reduced by antidepressive treatment
###end article-title 74
###begin article-title 75
Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones
###end article-title 75
###begin article-title 76
Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage
###end article-title 76
###begin article-title 77
S100 beta protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques
###end article-title 77
###begin article-title 78
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease
###end article-title 78
###begin article-title 79
The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease
###end article-title 79
###begin article-title 80
###xml 51 56 <span type="species:ncbi:9606">human</span>
Differential expression of S100B and S100A6 in the human fetal and aged cerebral cortex
###end article-title 80
###begin article-title 81
Immunohistochemical distribution of S-100 protein in the cerebral cortex with regard to the cause of death in forensic autopsy
###end article-title 81
###begin article-title 82
Specific acidic proteins of the nervous system.
###end article-title 82
###begin article-title 83
Increase in serum S100B protein level after a swimming race
###end article-title 83
###begin article-title 84
###xml 47 51 <span type="species:ncbi:10116">rats</span>
Changes in S100B cerebrospinal fluid levels of rats subjected to predator stress
###end article-title 84
###begin article-title 85
Relationship between stress and circulating levels of S100B protein
###end article-title 85
###begin article-title 86
###xml 44 48 <span type="species:ncbi:10116">rats</span>
Serum S100B protein is increased in fasting rats
###end article-title 86
###begin article-title 87
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Increased levels of serum S100B protein in critically ill patients without brain injury
###end article-title 87
###begin article-title 88
###xml 67 75 <span type="species:ncbi:9606">patients</span>
S100B is a sensitive but not specific prognostic index in comatose patients after cardiac arrest
###end article-title 88
###begin article-title 89
###xml 82 90 <span type="species:ncbi:9606">patients</span>
Effects of head and extracranial injuries on serum protein S100B levels in trauma patients
###end article-title 89
###begin article-title 90
Raised serum S100B levels after acute bone fractures without cerebral injury
###end article-title 90
###begin article-title 91
Nuclear expression of S100B in oligodendrocyte progenitor cells correlates with differentiation toward the oligodendroglial lineage and modulates oligodendrocytes maturation
###end article-title 91
###begin article-title 92
###xml 87 102 <span type="species:ncbi:10090">transgenic mice</span>
Visualization of S100B-positive neurons and glia in the central nervous system of EGFP transgenic mice
###end article-title 92
###begin article-title 93
S100B expression in and effects on microglia
###end article-title 93
###begin article-title 94
###xml 72 75 <span type="species:ncbi:9685">cat</span>
Immunohistochemical localization of the S-100 beta protein in postnatal cat visual cortex: spatial and temporal patterns of expression in cortical and subcortical glia
###end article-title 94
###begin article-title 95
###xml 76 92 <span type="species:ncbi:39310">Gallotia galloti</span>
S100 immunoreactive glial cells in the forebrain and midbrain of the lizard Gallotia galloti during ontogeny
###end article-title 95
###begin article-title 96
###xml 56 59 <span type="species:ncbi:10116">rat</span>
S100 protein expression in subpopulations of neurons of rat brain
###end article-title 96
###begin article-title 97
###xml 90 93 <span type="species:ncbi:10116">rat</span>
S100 immunoreactivity in a subpopulation of oligodendrocytes and Ranvier's nodes of adult rat brain
###end article-title 97
###begin article-title 98
Spatial and temporal expression of S100B in cells of oligodendrocyte lineage
###end article-title 98
###begin article-title 99
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 73 78 <span type="species:ncbi:10090">mouse</span>
Cell-specific expression of high levels of human S100 beta in transgenic mouse brain is dependent on gene dosage
###end article-title 99
###begin article-title 100
###xml 46 49 <span type="species:ncbi:10116">rat</span>
S-100 beta has a neuronal localisation in the rat hindbrain revealed by an antigen retrieval method
###end article-title 100
###begin article-title 101
###xml 71 74 <span type="species:ncbi:10116">rat</span>
Immunocytochemical localization of S-100 protein in the brain of adult rat. An ultrastructural study
###end article-title 101
###begin article-title 102
Histochemistry and immunocytochemistry of the developing ependyma and choroid plexus
###end article-title 102
###begin article-title 103
Glial progenitors in the CNS and possible lineage relationships among them
###end article-title 103
###begin article-title 104
###xml 59 64 <span type="species:ncbi:9606">human</span>
Immunocytochemical characterization of S-100 beta-positive human T-lymphocytes by a double immunostaining method
###end article-title 104
###begin article-title 105
Macrophages express glial markers
###end article-title 105
###begin article-title 106
###xml 109 114 <span type="species:ncbi:9606">human</span>
Detection of the peripheral nervous system (PNS)-type glial fibrillary acidic protein (GFAP) and its mRNA in human lymphocytes
###end article-title 106
###begin article-title 107
###xml 161 166 <span type="species:ncbi:10090">mouse</span>
Recent evolutionary origin of the expression of the glial fibrillary acidic protein (GFAP) in lens epithelial cells. A molecular and genetic analysis of various mouse species
###end article-title 107
###begin article-title 108
###xml 72 77 <span type="species:ncbi:9606">human</span>
Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast
###end article-title 108
###begin article-title 109
Molecular identity, distribution and heterogeneity of glial fibrillary acidic protein: an immunoblotting and immunohistochemical study of Schwann cells, satellite cells, enteric glia and astrocytes
###end article-title 109
###begin article-title 110
Neuronal modulation of Schwann cell glial fibrillary acidic protein (GFAP)
###end article-title 110
###begin article-title 111
Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization
###end article-title 111
###begin article-title 112
Color modification of diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry
###end article-title 112
###begin article-title 113
Neuroglia and their reactions
###end article-title 113
###begin title 114
Figures and Tables
###end title 114
###begin p 115
###xml 104 109 <span type="species:ncbi:9606">human</span>
S100B immunoblot (DAKO, Glostrup, Denmark, dilution 1:500) indicating a single band of S100B protein in human brain homogenates.
###end p 115
###begin p 116
###xml 0 37 0 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink">GFAP- and S100B-single immunostaining</bold>
###xml 39 43 39 43 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 300 304 300 304 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 519 523 519 523 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 631 635 631 635 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 894 898 894 898 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 1080 1084 1080 1084 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(f) </bold>
###xml 1186 1190 1186 1190 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(g) </bold>
###xml 1282 1285 1282 1285 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(h)</bold>
###xml 1434 1438 1434 1438 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(i) </bold>
###xml 1520 1524 1520 1524 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(k) </bold>
###xml 1669 1674 1669 1674 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a, b </bold>
###xml 1685 1705 1684 1704 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d, e, f, g, h, I, k </bold>
###xml 1715 1741 1713 1739 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c, d (detail), k (detail) </bold>
GFAP- and S100B-single immunostaining. (a) GFAP immunohistochemistry of the border between temporal cortex and adjacent white matter selectively labels star-shaped astrocytes and their processes. Blood vessels appear to be GFAP-positive because of their close association with pericapillary endfeet. (b) In contrast, various glial cell types are expressing S100B in this brain region, such as star-shaped cells with astrocytic morphology (black arrow) and spheroid cells with oligodendrocytic morphology (white arrow). (c) S100B stained astrocytic end feet (arrow: glial perivascular membrane) surround vascular endothelial cells. (d) "Pearl necklet" alignment of S100B positive (black arrow) and negative (white arrow) cells with oligodendrocytic morphology are associated with fibre tracts of the corpus callosum. Cytoplasmic and nuclear distribution of S100B is shown in the detail-picture. (e) The ependymal layer [E] around the lateral ventricle shows only weak GFAP staining, whereas the subependymal layer [S] shows intense staining of astrocytes and astrocytic processes. (f) Strongly S100B immunopositive ependymal [E] and subependymal [S] layers around the lateral ventricle. (g) Ependymal cells of the choroid plexus do not express GFAP but are heavily stained for S100B (h); some S100B-positive cells display apical secrete granules; arrows indicate cells with cytoplasmic versus cytoplasmic and nuclear S100B expression. (i) S100B immunopositive CA1 hippocampal neurone. Neurones are rarely S100B positive. (k) S100B immunopositive lymphocytes and vascular smooth muscle cells. The detail picture shows a S100B stained lymphocyte from a blood smear. Bars: a, b = 100 mum; d, e, f, g, h, I, k = 50 mum; c, d (detail), k (detail) = 20 mum.
###end p 116
###begin p 117
###xml 0 53 0 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Double immunostaining and immunofluorescence staining</bold>
###xml 55 59 55 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 392 396 392 396 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 637 641 637 641 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 876 880 876 880 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 1029 1033 1029 1033 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(e) </bold>
###xml 1116 1120 1116 1120 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(f) </bold>
###xml 1243 1247 1243 1247 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(g) </bold>
###xml 1341 1343 1341 1343 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a </bold>
###xml 1354 1356 1353 1355 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b </bold>
###xml 1367 1369 1365 1367 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c </bold>
Double immunostaining and immunofluorescence staining. (a) S100B (red)/GFAP (black) double immunolabelling with haematoxylin-counterstaining (blue) revealed distinct populations of cells with astrocytic morphology in the temporal cortex. White arrows indicate S100B single positive cells with astrocytic morphology; black arrows indicate GFAP immunopositive cells with astrocytic morphology. (b) Temporal brain region (overview): The majority of GFAP immunopositive (black) astrocytes were found in the glial limitans and perivascular membrane or in the adjacent white matter. Less GFAP immunopositive cells were observed in the cortex. (c) Temporal cortex and adjacent white matter (higher magnification): S100B positive (red) radial fibres and oligodendrocytes (white arrows) are shown in comparison to GFAP positive (black) astrocytes; haematoxylin-counterstaining (blue). (d) Co-localization (yellow) of S100B (red) and MBP-positive (green) myelinated fibres, extending from the temporal cortex to the adjacent white matter. (e) Co-localization (yellow) of S100B (red) and MOG-positive (green) oligodendrocytes. (f) Co-localization (yellow) of S100B (red) and A2B5-immunopositive (green) O2A glial progenitor cells in the temporal cortex. (g) No co-localization (yellow) was observed for S100B (red) and microglial HLA-DR (green). Bars: a = 100 mum; b = 500 mum; c = 30 mum.
###end p 117
###begin p 118
###xml 59 69 59 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Annotation</italic>
Cell-type specific S100B- and GFAP-immunostaining pattern. Annotation:  immunonegative, + faint immunostaining, ++ strong immunostaining
###end p 118
###begin p 119
###xml 61 68 61 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 97 107 97 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Annotation</italic>
###xml 144 149 142 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DLPF </italic>
Quantification of S100B immunopositive cells with astrocytic versus oligodendrocytic morphology. Annotation: Values are given as mean +/- S.D.; DLPF dorsolateral prefrontal
###end p 119

